HS
HS2.F Henry Schein Inc
- Market cap
- EUR 8.73B
- P/E
- 25.2x
- P/B
- 3.09x
- ROE
- 13.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is HS2.F undervalued?
Graham numberHS2.F trades 85.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Henry Schein Inc fundamental analysis
No fundamental analysis for Henry Schein Inc yet.
Henry Schein Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Henry Schein Inc
Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments. The Global Distribution and Value-Added Services segment distributes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum, acrylics, articulators, abrasives, PPE product…
Full company profileHenry Schein Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Henry Schein Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 11.6B | 12.5B | 13.2B | 9.99B | 10.1B | 12.4B | 12.6B | 12.3B | 12.7B | 13.2B | 13.7B |
| Gross Profit | 3.23B | 3.40B | 3.60B | 3.09B | 2.81B | 3.67B | 3.83B | 3.86B | 4.02B | 4.11B | 4.37B |
| Operating Income | 817M | 859M | 893M | 733M | 567M | 860M | 878M | 695M | 731M | 758M | 812M |
| EBITDA | - | 1.07B | 982M | 916M | 727M | 1.07B | 977M | 851M | 912M | 964M | 1.10B |
| Net Income | 507M | 406M | 536M | 695M | 404M | 631M | 538M | 416M | 390M | 398M | 427M |
| EPS | - | 2.64 | 3.54 | 4.85 | 2.83 | 4.60 | 4.08 | 3.22 | 3.14 | 3.44 | 3.86 |
| Balance Sheet | |||||||||||
| Total Assets | 6.73B | 7.81B | 8.50B | 7.15B | 7.77B | 8.48B | 8.61B | 10.6B | 10.2B | 11.2B | 11.5B |
| Total Liabilities | 3.93B | 4.99B | 4.96B | 3.52B | 3.79B | 4.42B | 3.94B | 5.42B | 5.38B | 6.42B | 6.78B |
| Shareholders' Equity | 2.79B | 2.81B | 2.96B | 3.00B | 3.35B | 3.43B | 3.45B | 3.66B | 3.39B | 3.25B | 3.16B |
| Cash & Short-term Investments | 62.4M | 175M | 80.2M | 106M | 421M | 118M | 117M | 171M | 122M | 156M | 184M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 643M | 546M | 685M | 654M | 599M | 710M | 602M | 500M | 848M | 712M | 408M |
| Capital Expenditure | 70.2M | 62.4M | 71.3M | 76.2M | 49.0M | 79.0M | 96.0M | 187M | 187M | 191M | 173M |
| Free Cash Flow | - | 464M | 594M | 578M | 550M | 631M | 506M | 313M | 661M | 521M | 235M |
| Ratios | |||||||||||
| ROE | 18.1% | 14.5% | 18.1% | 23.2% | 12.1% | 18.4% | 15.6% | 11.4% | 11.5% | 12.3% | 13.5% |
| ROA | 7.5% | 5.2% | 6.3% | 9.7% | 5.2% | 7.4% | 6.3% | 3.9% | 3.8% | 3.5% | 3.7% |
| Net Profit Margin | 4.4% | 3.3% | 4.1% | 7.0% | 4.0% | 5.1% | 4.3% | 3.4% | 3.1% | 3.0% | 3.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Henry Schein Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | USD 29.1M | 0.19 | 7.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Sep 15, 2017.
Who owns Henry Schein Inc
- Insiders 0.84%
- Institutions 99.16%
- Public & others 0.00%
- Shares outstanding 111M
- Free float 90.8M
Henry Schein Inc company profile
- Company name
- Henry Schein Inc
- Ticker
- HS2.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 25,000
- Fiscal year end
- December
- Address
- 135 Duryea Road, Melville, NY, United States, 11747
- Phone
- 631 843 5500
- Website
- henryschein.com
About Henry Schein Inc
Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments. The Global Distribution and Value-Added Services segment distributes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum, acrylics, articulators, abrasives, PPE products, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as provides equipment repair services, financial services on a non-recourse basis, continuing education services for practitioners, consulting, and other services. It also markets and sells a portfolio of consumable merchandise under its own corporate brand. The Global Specialty Products segment engage in manufacturing, marketing, and sales of dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products, and other health care-related products and services. The Global Technology segment is involved in the development and distribution of practice management software, e-services, and other products which are distributed to health care providers. The company serves dental practices, laboratories, physician practices, and ambulatory surgery centers, as well as government, institutional health care clinics, home health providers, and other alternate care clinics. It has a strategic partnership with GoTu Technology to help dental practices address ongoing staffing challenges. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.
Henry Schein Inc management
10- Mr. Andrea AlbertiniChief Executive Officer of Global Distribution & Technology · born 1970
- Mr. Frederick M. LoweryCEO & Director · born 1971
- Mr. Emmanuel CapraisSenior VP & CFO · born 1975
- Ms. Olga TimoshkinaVP of Corporate Finance & Chief Accounting Officer
- Mr. Christopher PendergastSenior VP & CTO · born 1963
- Mr. Graham StanleyVP of Investor Relations & Strategic Finance Project Officer
- Ms. Kelly Murphy J.D.Senior VP & General Counsel · born 1981
- Timothy VassilakosVice President of Global Corporate Communications
- Ms. Christine Z. SheehySenior VP & Chief Human Resources Officer · born 1968
- Mr. Mark HillebrandtVP & Chief Data Revenue Officer